South Africa has recorded 18 laboratory-confirmed mpox cases and one probable case as of Wednesday, 17 September 2026, according to the Department of Health and the National Institute for Communicable Diseases. The department dated its alert 17 September, and NICD published it online on 18 September. Officials said the recent pace requires sustained public cooperation to contain transmission.
Fifteen of the 19 confirmed-and-probable reports were in the Western Cape, particularly Cape Town, while Gauteng accounted for three and KwaZulu-Natal for one. The provincial figures add to 19 because they include the probable case; they should not be described as 19 laboratory confirmations.
What the numbers show
Officials said 13 of the reports were recorded between 13 August and 17 September, an increase they interpret as evidence of rapid local transmission. A 7 September clinician alert had counted ten cases from 1 January through 3 September, eight of them in the Western Cape. The newer national notice is therefore the current snapshot.
The patients and probable case range from 23 to 50 years old, with a median age of 36.5. Eighteen are male and one is female. Those demographics describe the cases detected so far; they do not mean mpox can infect only adults, men or any particular community. Health authorities stress that anyone can be affected after relevant exposure.
One recent report involved a traveller who returned from Spain on 14 September after being told there that the case was probable. South African officials said they were contacting Spanish counterparts for laboratory results. Until that confirmation is received, the case must remain described as probable rather than confirmed or locally acquired.
Symptoms, exposure and when to seek care
Mpox spreads mainly through close physical contact with an infected person, including contact with lesions or body fluids, and through contaminated materials such as bedding, clothing or towels. Prolonged face-to-face exposure to respiratory droplets can also transmit the virus. The alert does not support treating casual presence in a city or ordinary brief contact as proof of infection.
Symptoms can include fever, headache, muscle aches, back pain, fatigue and a rash or lesions on the face, hands, feet, genitals or elsewhere. The department says symptoms usually appear six to 13 days after exposure but can take five to 21 days. People with compatible symptoms, especially after close contact with a confirmed or suspected case, should seek medical care and avoid close contact while being assessed.
The government says it has obtained limited supplies of the MVA-BN vaccine and the antiviral tecovirimat with World Health Organization support. Authorities will decide where and how to use them. That is a targeted outbreak-response stock, not an announcement that vaccination is available to everyone or that pharmacies and clinics can dispense treatment on demand.
Limited medical supplies are not a public rollout
NICD guidance for clinicians says most management is supportive and that tecovirimat may be considered for severe disease through the South African Health Products Regulatory Authority's Section 21 process. This means the medicine is not a routine, proven cure. Individual treatment and vaccine decisions belong with health authorities and qualified clinicians.
The public-health task is early detection without stigma. People who fear discrimination may delay testing or care, making transmission harder to interrupt. Accurate reporting therefore needs both urgency and restraint: 18 cases are confirmed, one remains probable, most reports are concentrated in Cape Town, and the next meaningful update will be laboratory confirmation, contact-tracing results or a clearly defined vaccination plan.
The accompanying photograph is an archival image of President Cyril Ramaphosa, used to identify the national government responsible for the response. It was not taken during the mpox alert and does not show a patient, clinic, vaccination event or current outbreak location.
